These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 19541663

  • 1. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Soliman N.
    Nephrol Dial Transplant; 2009 Sep; 24(9):2951; author reply 2951-2. PubMed ID: 19541663
    [No Abstract] [Full Text] [Related]

  • 2. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Proesmans W, Van Dyck M, Devriendt K.
    Nephrol Dial Transplant; 2009 Apr; 24(4):1335-8. PubMed ID: 19147669
    [Abstract] [Full Text] [Related]

  • 3. [RAS blockade].
    Jin C, Ito S.
    Nihon Rinsho; 2004 Oct; 62(10):1880-4. PubMed ID: 15500134
    [Abstract] [Full Text] [Related]

  • 4. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 5. [Kidney involvement in hereditary osteo-onychodysplasia].
    Kozlovskaia NL, Tareeva IE, Popova VV, Miroshnichenko NG, Stavrovskaia EV.
    Ter Arkh; 1997 Sep; 69(6):37-9. PubMed ID: 9297271
    [Abstract] [Full Text] [Related]

  • 6. Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome.
    Supavekin S, Surapaitoolkorn W, Tancharoen W, Pattaragarn A, Sumboonnanonda A.
    Pediatr Int; 2012 Dec; 54(6):793-7. PubMed ID: 22621380
    [Abstract] [Full Text] [Related]

  • 7. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T.
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract] [Full Text] [Related]

  • 8. Dual renin-angiotensin system blockade: on the target.
    Robles NR.
    Int J Clin Pract; 2008 Aug; 62(8):1134-6. PubMed ID: 18705817
    [No Abstract] [Full Text] [Related]

  • 9. Dual blockade of renin-angiotensin system in primary focal segmental glomerulosclerosis.
    Singh A.
    Nephrol Dial Transplant; 2006 Mar; 21(3):830-1. PubMed ID: 16278255
    [No Abstract] [Full Text] [Related]

  • 10. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 11. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
    Robles NR, Ruiz Jiménez B, Hernández Gallego R, Ruiz-Calero R, Sánchez Casado E, Cubero JJ.
    Eur J Intern Med; 2009 Mar; 20(2):186-9. PubMed ID: 19327610
    [Abstract] [Full Text] [Related]

  • 12. Should all patients with significant proteinuria take a renin-angiotensin inhibitor?
    Thomas G, Nally JV.
    Cleve Clin J Med; 2015 Nov; 82(11):716-8. PubMed ID: 26540320
    [No Abstract] [Full Text] [Related]

  • 13. The case for dual Renin-Angiotensin system inhibition.
    Hirsch S.
    Arch Intern Med; 2009 Nov 09; 169(20):1931; author reply 1931. PubMed ID: 19901153
    [No Abstract] [Full Text] [Related]

  • 14. Dual renin-angiotensin system blockade in heart failure.
    McMurray JJ, Granger CB, Ostergren J, Yusuf S, Pfeffer MA, Swedberg K.
    J Am Coll Cardiol; 2009 Jul 14; 54(3):278; author reply 279-80. PubMed ID: 19589444
    [No Abstract] [Full Text] [Related]

  • 15. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
    Bensman A, Niaudet P.
    Pediatr Nephrol; 2010 Jul 14; 25(7):1197-9. PubMed ID: 20195644
    [Abstract] [Full Text] [Related]

  • 16. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J.
    J Fam Pract; 2009 Jun 14; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract] [Full Text] [Related]

  • 17. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
    Ku E, Park J, Vidhun J, Campese V.
    Arch Intern Med; 2009 Jun 08; 169(11):1015-8. PubMed ID: 19506167
    [No Abstract] [Full Text] [Related]

  • 18. Aliskiren combined with losartan in diabetes and nephropathy.
    Lindner T.
    N Engl J Med; 2008 Sep 04; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
    [No Abstract] [Full Text] [Related]

  • 19. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV, Deedwania PC.
    Am J Cardiol; 2008 Nov 01; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract] [Full Text] [Related]

  • 20. Aliskiren as an antiproteinuric add-on therapy in primary membranous nephropathy.
    Gupta A, Khaira A, Singh B, Bhowmik DM, Tiwari SC.
    Clin Exp Nephrol; 2009 Aug 01; 13(4):402-403. PubMed ID: 19255825
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.